Search clinical trials for: Deferasirox (ICL670)

Total 103 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Myelodysplastic Syndromes | Transfusion Dependent Iron Overload

Germany
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)

Non-transfusion Dependent Thalassemia

Thailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
City of Hope Medical Center

Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Crolll Gmbh
University of Magdeburg; Estimate, GmbH

Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

Non-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed Distribution

Germany
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Abramson Cancer Center of the University of Pennsylvania

Completed

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients

United States
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Chronic Iron Overload Due to Transfusion-dependant Anemias

Italy, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
Novartis Pharmaceuticals

Completed

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Iron Overload

Spain
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Hereditary Hemochromatosis

Belgium, France, Russian Federation, Romania, Slovakia, Spain, Switzerland
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Novartis Pharmaceuticals

Completed

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS)

Iron Overload

United Kingdom, Italy, Oman, United Arab Emirates, Lebanon, Thailand, Egypt
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Transfusional Iron Overload

Italy
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Hepatic Impairment

Germany
Novartis Pharmaceuticals

Terminated

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (MACS1574)

Myelodysplastic Syndrome | Transfusional Iron Overload

Spain, France, Italy, South Africa
Novartis Pharmaceuticals

Completed

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Myelodysplastic Syndrome | Thalassemia

Russian Federation
Novartis Pharmaceuticals

Completed

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload | β-thalassemia

Italy
Novartis Pharmaceuticals

Completed

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Transfusional Iron Overload

United States, Greece, Italy
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Anemia | Hemosiderosis

United States, Germany, Belgium, United Kingdom, Italy, Canada, France
Novartis Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Transfusion-dependent Iron Overload

Egypt, Greece, Hong Kong, Taiwan, Germany, United Kingdom, Belgium, Italy, Spain, France, Israel, Korea, Republic of, Turkey, China, Australia, Denmark, Austria, Switzerland, Netherlands, South Africa, Lebanon, Malaysia, Thailand
Novartis Pharmaceuticals

Completed

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Transfusional Iron Overload | β-thalassemia Major | Pediatric Rare Anemia

Italy, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Iron Overload

Germany
Novartis Pharmaceuticals

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Sickle Cell Disease

United States, Italy, United Kingdom, France, Canada
Novartis Pharmaceuticals

Completed

Post Hematopoietic Stem Cell Transplantation

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Turkey
Novartis Pharmaceuticals

Completed

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Beta-Thalassemia

United States
Weill Medical College of Cornell University

Unknown

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Thalassemia

United States
Novartis Pharmaceuticals

Completed

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Iron Overload | Myelodysplastic Syndrome

United States, Canada
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Aplastic Anemia

Russian Federation
Boston Children's Hospital
Novartis

Completed

Pilot Study for Patients With Poor Response to Deferasirox

Sickle Cell Disease | Thalassemia Major | Transfusion-dependent Hemachromatosis

United States
Novartis Pharmaceuticals

Completed

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

Myelodysplastic Syndromes

China, Hong Kong, Switzerland, United Kingdom, Italy, Thailand, Bulgaria, Greece, Russian Federation, Canada, Mexico, Australia, Denmark, Malaysia, New Zealand, United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
Novartis Pharmaceuticals

Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)

Non-transfusion-dependent Thalassemia | Transfusion-dependent Thalassemia

Egypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
Novartis Pharmaceuticals

Withdrawn

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (CENTAurus)

Thalassemia (Transfusion Delendent)
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Novartis Pharmaceuticals

Completed

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Low and Int 1-risk Myelodysplastic Syndrome

Germany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

Sickle Cell Disease

Netherlands
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Novartis Pharmaceuticals

Completed

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload (CORDELIA)

Transfusional Hemosiderosis | Transfusional Iron Overload

Taiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (THALASSA)

Non-transfusion Dependent Thalassemia

Greece, Taiwan, Italy, United Kingdom, Lebanon, Turkey, Malaysia, Thailand, United States
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States

Search clinical trials for: Deferasirox (ICL670)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations